US 11,813,292 B2
Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)
Patrick Soon-Shiong, San Diego, CA (US); Hans G Klingemann, San Diego, CA (US); Laurent H Boissel, San Diego, CA (US); Himani Chinnapen, San Diego, CA (US); and Abhijit Dandapat, San Diego, CA (US)
Assigned to Immunity Bio, Inc., Culver City, CA (US)
Appl. No. 16/966,868
Filed by ImmunityBio, Inc., Culver City, CA (US)
PCT Filed Mar. 11, 2019, PCT No. PCT/US2019/021647
§ 371(c)(1), (2) Date Jul. 31, 2020,
PCT Pub. No. WO2019/177986, PCT Pub. Date Sep. 19, 2019.
Claims priority of provisional application 62/641,915, filed on Mar. 12, 2018.
Prior Publication US 2021/0038645 A1, Feb. 11, 2021
Int. Cl. A61K 35/17 (2015.01); A61K 38/17 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 38/1774 (2013.01)] 3 Claims
 
1. A method for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both, in a subject in need thereof, the method comprising:
administering to the subject, intravenously or by injection, a therapeutically effective amount of a genetically modified cell comprising a chimeric antigen receptor (CAR) that specifically binds CD33, wherein the CAR comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 16, and
wherein the genetically modified cell is a T cell or NK-92 cell.